|
US2020172865A1
|
|
Modified Cell with Enhanced Migration Capability
|
|
WO2020086989A1
|
|
Increase or maintaining t-cell subpopulations in adoptive t-cell therapy
|
|
CN111019905A
|
|
CAR modified cell and application thereof in preparation of autoimmune disease drugs
|
|
CN110511912A
|
|
The function point analysis of immunocyte
|
|
US2020069732A1
|
|
Modulation of cell function for immunotherapy
|
|
US2020071400A1
|
|
CAR T Therapy through Uses of Co-stimulation
|
|
CN111197032A
|
|
Chimeric antigen receptor cell secretion therapeutics
|
|
US2020155598A1
|
|
Modified cell expressing therapeutic agent and uses thereof
|
|
US2019314411A1
|
|
Modified cell expansion and uses thereof
|
|
US2019125798A1
|
|
Chimeric antigen receptor (CAR) and T cell receptor (TCR) Modified T cells
|
|
US2019216851A1
|
|
Modified cell expansion and uses thereof
|
|
US2019000878A1
|
|
Lymphocyte Cell Lines and Uses Thereof
|
|
CN110770348A
|
|
Preparation of chimeric antigen receptor cells and uses thereof
|
|
US2018179289A1
|
|
Use of chimeric antigen receptor modified cells to treat cancer
|
|
US2018153977A1
|
|
Humanized anti-CD19 antibody and use thereof with chimeric antigen receptor
|
|
WO2018064921A1
|
|
Use of chimeric antigen receptor modified cells to treat cancer
|
|
CN109219445A
|
|
The application of Chimeric antigen receptor modified cells treating cancer
|
|
US2018112179A1
|
|
Modified cells for production of blood cells
|
|
EP2864483A1
|
|
Transcription activator-like effector assembly
|
